Changes

Jump to navigation Jump to search
86 bytes added ,  09:21, 3 September 2024
Archive Daily Show links, because of https://www.hollywoodreporter.com/tv/tv-news/daily-show-alumni-clip-archive-loss-1235934107/
Line 51: Line 51:  
Abdo (1994) reported on the effects of administering sodium selenate in the drinking water for 13 weeks. It was estimated that the "no-observed adverse level" in rat was 0.4 mg/kg per day of sodium selenate for 13 weeks. Doses of 0.6 mg/kg or 1.1 mg/kg  per day for 13 weeks caused changes in mortality, body weight depression, decreased water consumption, and renal papillary lesions. However, these were chronic studies so that rats received a total dose of 54.6 mg/kg or 100.1 mg/kg sodium selenate over 13 weeks.
 
Abdo (1994) reported on the effects of administering sodium selenate in the drinking water for 13 weeks. It was estimated that the "no-observed adverse level" in rat was 0.4 mg/kg per day of sodium selenate for 13 weeks. Doses of 0.6 mg/kg or 1.1 mg/kg  per day for 13 weeks caused changes in mortality, body weight depression, decreased water consumption, and renal papillary lesions. However, these were chronic studies so that rats received a total dose of 54.6 mg/kg or 100.1 mg/kg sodium selenate over 13 weeks.
   −
Aasif Mandvi ran a [https://www.cc.com/video/jucn2a/the-daily-show-with-jon-stewart-a-simple-plot story] on selenium pollution of Idaho rivers as a consequence of phosphate mining.
+
Aasif Mandvi ran a [https://web.archive.org/web/20240423122448/https://www.cc.com/video/jucn2a/the-daily-show-with-jon-stewart-a-simple-plot story] on selenium pollution of Idaho rivers as a consequence of phosphate mining.
    
==Selenium Ingestion and Aversions==
 
==Selenium Ingestion and Aversions==
Line 89: Line 89:  
Corcoran NM et al. 2010b.  Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br J Cancer. 103:462-8. PMID 20648008
 
Corcoran NM et al. 2010b.  Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br J Cancer. 103:462-8. PMID 20648008
   −
Mandvi, A. A Simple Plot. The Daily Show with Jon Stewart, aired June 14, 2012. https://www.cc.com/video/jucn2a/the-daily-show-with-jon-stewart-a-simple-plot
+
Mandvi, A. A Simple Plot. The Daily Show with Jon Stewart, aired June 14, 2012. https://web.archive.org/web/20240423122448/https://www.cc.com/video/jucn2a/the-daily-show-with-jon-stewart-a-simple-plot
    
Reid ME et al.  2004 A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 18:69–74 PMID 15487766
 
Reid ME et al.  2004 A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 18:69–74 PMID 15487766
    
van Eersel J et al. 2010. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. PNAS 107:13888-93. PMID 20643941
 
van Eersel J et al. 2010. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. PNAS 107:13888-93. PMID 20643941

Navigation menu